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Based on the integral theory, tension-free placement of a mid-urethral sling (MUS) for 
female stress urinary incontinence (SUI) has gained substantial popularity owing to 
the ease of the procedure and its effectiveness. Published series with long-term fol-
low-up show continence rates after the MUS procedure ranging from 70% to 80%. 
Complication rates after MUS procedures are usually low. This review aimed to de-
scribe the historical change and the current use of the MUS. We discuss the efficacy 
and complications of various MUS procedures and the current strategies for managing 
failed slings.
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INTRODUCTION
After the introduction of the integral theory and the devel-
opment of the mid-urethral sling (MUS), MUS is now con-
sidered a standard surgical option for the management of 
female stress urinary incontinence (SUI). As the materials 
and surgical techniques of SUI surgery evolve, surgeons 
are faced with the concern of choosing the optimal manage-
ment option. This review aimed to describe the historical 
change and the current use of the MUS. We discuss the effi-
cacy and complications of various MUS procedures and the 
current strategies for managing failed slings.
MECHANISM OF ACTION: THE INTEGRAL 
THEORY
In 1990, Petros and Ulmsten described the integral theory 
of female urinary continence, a concept that would define 
the modern approach of anti-incontinence surgery [1]. The 
theory proposes that a physiologic backboard is created 
through fixation of the middle region of the urethra to the 
pubic bone, via the pubourethral ligaments [2]. Loss of this 
backboard, which is critical to the continence mechanism, 
inhibits normal urethral coaptation when the intra-ab-
dominal pressure is increased and results in urinary 
incontinence. The three pelvic organs, bladder, vagina, and 
rectum, are suspended from the pelvic brim by three sus-
pensory ligaments, pubourethral, cardinal/uterosacral, 
and arcus tendineus fascia pelvis. The vaginal fascia is 
closely linked to the suspensory ligaments and the perineal 
body. Three directional muscles transmit tension to the or-
gans to give them position, shape, and strength. The clin-
ical application of this concept was evident in subsequent 
repositioning of the sling to a more distal location beneath 
the urethra, appropriately described as the MUS. “Ten-
sion-free” polypropylene tapes have been applied at the 
mid-urethra to cure stress incontinence. Reinforcement of 
the muscle insertion points, the ligaments, restores open-
ing and closing muscle forces and, therefore, function.
EVOLUTION OF THE ROUTE: MID-URETHRAL 
SLING TYPES
Since the introduction of the MUS technique, significant 
global experience with this procedure has proven it to be 
an effective treatment for SUI. Following initial reports by 
Ulmsten on a new surgical procedure to treat SUI, the ten-
sion-free vaginal tape (TVT) procedure has been used glob-
ally owing to its reduced invasiveness and high success rates 
[3]. Subsequently, other retro pubically implanted devices, 
such as the SPARC (American Medical Systems Research 
Corp., Minnetonka, MN, USA) and intravaginal sling-Korean J Urol 2010;51:223-232
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TABLE 1. Commercial kits available for midurethral sling place-
ment
Name Manufacturer Approach
Retropubic
Transvaginal tape Gynecare
a Bottom-to-top
Suprapubic arc (SPARC
®)A M S
b Top-to-bottom
IVS Tunneler US surgical
c Bottom-to-top
Transobturator
Monarc AMS Outside-in
TVT-O Ethicon
d Inside-out
ObTape Mentor
e Outside-in
ObTryx Boston scientific
f Outside-in
Obturator IVS Tunneler US surgical Outside-in
UraTape
® Porgès-mentor
g Inside-out
Aris
® Coloplast
h Outside-in
TOT
® Dow
i Outside-in
Other
MiniArc
® AMS NA
Secur
® Gynecare NA
NA: not applicable, TVT-O: transobturator vaginal tape, IVS: in-
travaginal slingplasty, All these kits use a polypropylene mesh 
sling. 
a: Gynecare
® Inc., Menlo Park, CA. 
b: American Medical Sys-
tems Research Corp., Minnetonka, MN. 
c: US Surgical, Norwalk, 
CT. 
d: Ethicon Inc., Somerville, NJ. 
e: Mentor Corp., Santa Barbara 
CA. 
f: Boston Scientific Scimed Inc., Maple Grove, MN. 
g: Le Plessis, 
Robinson, France. 
h: Coloplast A/S, Copenhagen, Denmark, 
i: Dow 
Medics, Korea
FIG. 1. TVT-Secur device after insertion. (A) TVT-Secur “U” type. (B) TVT-Secur “H” type (Figures printed with permission from 
TVT-S; TVT-Secur, Gynecare, Menlo Park, CA, USA).
plasty (IVS) (US Surgical, Norwalk, CT, USA) slings, make 
sling procedures even less invasive, more cost-effective, 
and sometimes only used for patent issues (Table 1). As the 
result of efforts to develop safer and less invasive proce-
dures to avoid blind passage of a needle through the retro-
pubic region, the trans-obturator tape (TOT) procedure 
was introduced by Delorme [4]. New products continue to 
be developed and introduced as safe and effective alter-
natives to retro pubic or trans-obturator slings. Single-in-
cision MUS, the TVT-SECUR (Gynecare, Menlo Park, CA, 
USA), the MiniArc (American Medical Systems, Minne-
tonka, MN, USA), the Mini-Sling (ProSurg, San Jose, CA, 
USA), and the Prefyx PPS System (Boston Scientific, 
Natick, Massachusetts) were developed to minimize the 
risks by the short course of the devices. The TVT-SECUR 
consists of prolene mesh, 8 cm in length, that is advanced 
into the endopelvic fascia through a small vaginal incision. 
For the U-type method, the inserters are introduced into 
the paraurethral space oriented to 45
o from the sagittal 
midline and are advanced upward until the back edge of 
the pubic bone is reached, creating a U-shaped sling. For 
the H-type method, the inserters are introduced into the 
obturator internus muscle parallel to the floor, thus creat-
ing a hammock(H)-shaped sling (Fig. 1). 
EFFICACY OF THE MID-URETHRAL SLINGS
According to the 5-year outcomes of the TVT procedure 
published by Doo et al, the overall success rate was 94.9%, 
with an 86.6% patient satisfaction rate [5]. The cure rates 
of the TOT procedure were noted to range from 51% to 95%, 
depending on the definition used for success, the study in-
struments, and the study population [6,7]. To date, many 
randomized controlled trials (RCTs) comparing different 
types of MUS have been performed. 
1. TVT vs. pubovaginal sling
Several RCTs have been conducted to compare the TVT and 
pubovaginal sling as treatments for SUI. Bai et al showed 
that the rectal fascia pubovaginal sling outperformed both 
TVT and Burch colposuspension, with 92.8% of the pa-
tients experiencing cure at the 12-month follow-up, com-
pared with 87.8% of the Burch colposuspension group and 
87% of TVT patients [8]. Wadie et al reported similar con-
tinence rates between TVT (92%) and the pubovaginal 
sling (92%) [9]. According to meta- analyses, TVT and pubo-
vaginal slings showed similar continence rates [odds ratio Korean J Urol 2010;51:223-232
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TABLE 2. Randomized controlled trials comparing TVT with other mid-urethral sling procedures as the primary treatment for stress 
urinary incontinence: subjective and objective cure rates
Reference Cases
Follow-up 
(months)
Cure rate
Objective (%) Subjective (%)
Bai 2005 [8]
  TVT 
  Puvovaginal sling 
Wadie 2005 [9]
  TVT
  Rectus fascia sling
Rechberger 2003 [11]
  TVT
  IVS
Meschia 2006 [12]
  TVT
  IVS
Tseng 2005 [13]
  TVT
  SPARC
Gandhi 2005 [14]
  TVT
  SPARC
Enzelsberger 2005 [15]
  TVT 
  Monarc 
Laurikainen 2006 [16]
  TVT 
  TVT-O 
Lee 2007 [17]
  TVT 
  TVT-O 
31
28
25
28
50
50
95
95
31
31
73
49
52
53
136
131
60
60
12
6
13.5
24
25
4.25
15
2.1
13
87
92.8
92
92.9
88
80
85/86
72/75
80.7
87.1
95
70
86
84
98.5
95.4
86.8
86.8
NR
NR
NR
87
78
NR
86
60
NR
Non-significant 
difference
NR
TVT: tension-free vaginal tape, IVS: intravaginal slingplasty, NR: not reported
(OR): 0.82; 95% confidence interval (CI): 0.42-1.59; p=0.55] 
[10]. RCTs comparing TVT with other MUS procedure are 
listed in Table 2.
2. TVT vs. other retropubic tension-free mid-urethral slings
The largest trial was recently published by Meschia et al, 
who reported outcomes on 190 patients randomly assigned 
1:1 to TVT or IVS [12]. The study showed significantly high-
er continence rates for patients treated with TVT, regard-
less of the applied definition of continence. TVT outper-
formed IVS, considering the success rates evaluated accor-
ding to any definition of continence (OR: 0.51; 95% CI: 0.31- 
0.83; p=0.007) and the presence of a negative stress test 
(OR: 0.47; 95% CI: 0.28-0.82; p=0.007). The subjective cure 
rates were not different (OR: 0.63; 95% CI: 0.37-1.09; p= 
0.10) [10]. A comparative study between TVT and SPARC 
reported similar continence rates in the two arms (87.1% 
vs. 80.7%) and similar complication rates across all the as-
sessable parameters [13]. 
3. Retropubic vs. trans-obturator tension-free mid-ure-
thral slings
When comparing the TVT procedure to the TVT-O proce-
dure, Laurikainen et al reported that the objective cure 
rates, defined as negative cough stress test at 2 months 
postoperatively, were 98.5% for the TVT group and 95.4% 
for the TVT-O group [16]. Subjective cure rates as demon-
strated by improvement on questionnaire scores were sim-
ilarly high in both groups.
　Lee et al randomly assigned 120 women to the TVT or 
TVT-O procedures [17]. The only significant differences be-
tween the groups were the mean operative time (TVT, 15.2 
min; TVT-O, 11.5 min) and sling length used (TVT, 23.1 cm; 
TVT-O, 16.1 cm). The rates of cure (TVT, 86.8%; TVT-O, 
86.8%), improvement (TVT, 6.6%; TVT-O, 8.2%) and fail-
ure (TVT, 6.6%; TVT-O, 5.0%) were similar. 
　A meta analysis by Latthe et al that compiled data from 
all available RCTs between retro pubic and trans-obturator 
slings showed similar subjective cure rates between the 
groups [18]. These data indicate little clinical difference be-
tween the retro pubic and trans-obturator approaches 
(Table 2).
4. Trans-obturator vaginal tape ‘inside-out’ vs. ‘outside-in’
A prospective study to compare the efficacy and safety of 
the ‘inside-out’ (TVT-O) and ‘outside-in’ (TOT) trans-ob-
turator tape procedures reported that TVT-O and TOT 
showed similar cure rates (86% vs. 92%) [19]. Approxi-Korean J Urol 2010;51:223-232
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TABLE 4. Comparisons of the changes in outcome measures between the U- and H-type methods
Variables
Total U-type method H-type method p-value
U vs. H
a
Preop. Postop. Preop. Postop. Preop. Postop.
I-QoL
Avo/Lim 41.8 71.3
b 41.8 75.3
b 41.8 67.2
b 0.022
Psychosocial impacts 43.3 71.9
b 43.4 76.0
b 43.2 67.7
b 0.021
Social embarrassment 34.7 74.9
b 33.9 79.6
b 35.5 70.0
b 0.015
ICIQ-FLUTS
Filling sum 6.18 3.60
b 6.20 3.18
b 6.15 4.04
b 0.022
Voiding sum 2.58 1.74
b 2.91 1.86
b 2.23 1.61
b 0.276
Incontinence sum 8.55 3.46
b 8.76 2.82
b 8.33 4.12
b 0.006
Sexual function score 1.74 0.87
b 1.81 0.81
b 1.66 0.94
b 0.421
QoL score 7.77 3.46
b 7.90 2.80
b 7.64 4.15
b 0.007
I-VAS 6.82 1.36
b 6.90 1.03
b 6.75 1.69
b 0.056
Voiding diary parameters
Micturition/24 hours 9.03 7.97
b 8.99 8.02
b 9.07 7.92
b 0.218
Nocturia 1.25 0.68
b 1.28 0.68
b 1.23 0.69
b 0.615
Urgency episode/24 hours 2.37 1.22
b 2.88 1.40
b 1.86 1.04
b 0.329
Uroflowmetry parameters
Qmax 25.7 24.3 24.8 23.7 26.6 25.0 0.576
PVR 18.0 20.1 18.2 20.6 17.8 19.6 0.306
Preop: preoperative, Postop: postoperative, Avo/Lim: avoidance and limiting behavior, ICIQ-FLUTS: international consultation on 
incontinence questionnaire- female lower urinary tract symptoms, I-QoL: incontinence quality of life questionnaire, PVR: postvoid 
residuals, Qmax: maximum flow rate, QoL: quality of life, I-VAS: incontinence visual analogue scale, 
a: Comparison between U- and 
H-type methods, Mann-Whitney U test, or t-test, 
b: p＜0.05, comparison between pre- and postoperative, Wilcoxon signed rank test, 
or paired t-test with Bonferroni correction
TABLE 3. Surgical results of patients who underwent inside-out 
TVT-O and outside-in TOT procedures
TVT-O
(n=50)
TOT
(n=50)
p-value
Stress urinary incontinence
Cured 43 (86%) 46 (92%) 0.262
a
Improved 5 (10%) 2 (4%) 0.134
b
Failed 2 (4%) 2 (4%) 0.691
b
Subjective satisfaction
Very satisfied 31 (62%) 34 (68%) 0.338
a
Satisfied 17 (34%) 15 (30%) 0.415
a
Not satisfied 2 (4%) 1 (2%) 0.500
b
Patient would undergo repeat
 operation if symptoms recur
Yes 48 (96%) 47 (94%) 0.500
a
No 2 (4%) 3 (6%) 0.500
b
Recommend to other patients
Yes 48 (96%) 45 (90%) 0.218
a
No 2 (4%) 5 (10%) 0.218
b
TVT-O: transobturator vaginal tape, TOT: trans-obturator tape, 
Values are given as n (%), NS: not significant (p＞0.05), 
a: chi- 
square test, 
b: Fisher’s exact test
mately 1 year after surgery, parameters in the incon-
tinence quality of life (I-QoL) questionnaire improved sig-
nificantly in both groups, but there was no statistical differ-
ence between the groups. Patients satisfaction rates with 
TVT-O and TOT (96% vs. 98%) were similar (Table 3).
　Debodinance conducted a prospective comparative study 
of 100 SUI patients: 50 TVT-O vs. 50 Monarc [20]. The cure 
rate at 1 year was 94% in the TVT-O group vs. 90% in the 
Monarc group. 
5. TVT-SECUR U-type vs. H-type
Lee et al performed a prospective, multicenter randomized 
comparative study between the U-type and H-type TVT- 
SECUR procedures (Table 4) [21]. The overall objective 
cure rate was 83.9% (239 of 285): 87.5% (126 of 144) for the 
U-type vs. 80.1% (113 of 141) for the H-type (p=0.091). The 
overall subjective cure rate was 76.4% (217 of 284): 77.1% 
(111 of 144) for the U- type vs. 75.7% (106 of 140) for the 
H-type (p=0.786). Improvement in the I-QoL and domain 
scores of the International Consultation on Incontinence 
Questionnaire-Female Lower Urinary Tract Symptoms 
(filling and incontinence sum, QoL score) questionnaires 
and patients satisfaction favored the U-type method. 
　Meschia et al reported that the TVT-SECUR procedure 
was effective for the treatment of primary SUI with 78% 
and 81% subjective and objective cure rates, respectively. 
No significant differences were seen in success rates when 
the tape was inserted by either the U- or H-type method 
[22]. The TVT-SECUR procedure appears to be an effective 
treatment for women with primary SUI, with an overall 
success rate of 80%. Korean J Urol 2010;51:223-232
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THE MID-URETHRAL SLING IN SPECIFIC 
CLINICAL PROBLEMS
1. Detrusor underactivity
If patients show detrusor underactivity during pre-
operative uroflowmetry or urodynamics, we cannot expect 
successful surgical outcomes after MUS. There is a delicate 
balance after MUS implant between continence and ob-
struction, and it is difficult to estimate the optimal degree 
of tension to be applied during surgery, especially in case 
of detrusor underactivity. If the tape is too loose, incon-
tinence may persist. On the other hand, if the tape is too 
tight, urinary obstruction could result. Between 0% and 
13% complete urinary retention occurs following the TOT 
procedure [23,24], and tape sectioning or tape adjustment 
are necessary in up to 5% of the cases [6].
　The adjustable MUS has been shown to allow adjust-
ment of tension for a number of days after surgical inter-
vention, thus permitting correction of postoperative incon-
tinence or obstruction [25]. Maroto et al performed the 
trans-obturator adjustable tape procedure in 77 patients 
[26]. A total of 69 patients (90%) were objectively continent, 
5 (6.5%) had considerable improvement, and in 3 patients 
(3.5%), the treatment failed. Additional pelvic floor surgery 
did not have any significant influence (p=0.519), neither 
did the need for adjustment (p=0.323).
2. Mixed incontinence
While surgical correction of SUI is associated with good 
long-term success rates, urgency urinary incontinence 
(UUI), as an independent entity and as a co-factor in pa-
tients with SUI, remains difficult to treat. Whereas pa-
tients with mixed urinary incontinence (MUI) undergo an-
ti-incontinence procedures mainly to control predom-
inantly stress-related symptoms, there are unresolved is-
sues about the effect of pre-existing urgency symptoms on 
postsurgical outcomes, and what mechanisms may under-
lie any postoperative symptom changes.
　A few studies have suggested that UUI may improve af-
ter the TVT procedure. Rezapour and Ulmsten reported 
that not only SUI but also UUI was cured in 85% of the pa-
tients and significantly improved in 4% [27]. Segal et al re-
ported that the improvement rate of the irritative sub-
scales on the Urinary Distress Inventory (UDI) for patients 
with MUI was 87.8% [28]. Paick et al evaluated the outcome 
at least 6 months after the TVT, SPARC, and TOT proce-
dures in women with MUI [29]. The cure rates in women 
with MUI were similar following the TVT, SPARC, and 
TOT procedures (for SUI: TVT, 95.8%; SPARC, 90.0%; 
TOT, 94.0%; p=0.625, and for UUI: TVT, 81.9%; SPARC, 
86.4%; TOT, 82.0%; p=0.965). Low maximum urethral clo-
sure pressure and the presence of uninhibited detrusor 
contraction during cystometry were deemed independent 
risk factors for UUI treatment failure.
COMPLICATIONS ASSOCIATED WITH 
MID-URETHRAL SLINGS
The complication rates following MUS placement are usu-
ally considered low. With regard to intraoperative compli-
cations, bladder perforations have been reported to occur 
in 2.5-11.7% of cases, whereas significant bleeding is less 
common (0.5-2.5%). Postoperative complications included 
urinary tract infections (0.4-31.5%), de novo urgency (3.1- 
29%), transient or persistent voiding dysfunction (2.8-38%), 
and vaginal and/or bladder erosions (0.6-5.4%) [30]. De-
spite these encouraging figures, some cases of major com-
plications have been reported, including bowel, vascular, 
and nerve injuries; necrotizing fasciitis; ischiorectal ab-
scess; sepsis; and death.
1. Bladder, urethral, or vaginal perforation
Although the development of trans-obturator tapes or sin-
gle-incision slings may limit the rate of bladder perfo-
ration, urethral or vaginal perforation is another cause of 
concern regarding this approach. In a meta-analysis of 
randomized controlled trials comparing complications af-
ter MUS procedures, retro pubic approaches caused up to 
a 24% risk of bladder perforation [31]. According to the de-
vices, trends were identified in favor of TVT for causing 
bladder perforations, compared with IVS and SPARC. 
When compared with the retro pubic and trans-obturator 
approaches, bladder perforation (OR: 2.33; 95% CI: 
1.26-4.32; p=0.007) was significantly less common in the 
patients treated by trans- obturator tapes (Table 5). In a re-
cent study on TVT-SECUR, lateral vaginal wall perfo-
ration was found in 2.1% (3/141) of women treated with the 
hammock approach [21]. Neuman reported a 4% incidence 
of vaginal perforation in their first 100 cases [35]. The 
TVT-SECUR system requires a wider tunnel to prevent 
dragging of the vaginal submucosal connective tissue and 
perforation of the vaginal mucosa when placing the end of 
the device into the fibrous tissue of the internal obturator 
muscle.
2. Mesh erosions
Although the complications of bladder and vaginal erosion 
are well recognized, these complications are inadequately 
reported in the literature [31]. In a trial conducted in the 
United Kingdom and Ireland, 175 patients underwent TVT 
placement, of whom 6 had a tape-related complication 
within 5 years (erosion into the vagina, obstructed voiding, 
suprapubic extrusion, or erosion into the bladder), and 
some presented between 2 and 5 years postoperatively [36]. 
A further patient presented with vaginal erosion due to 
TVT placement after 5 years of follow-up and was not in-
cluded in the 5-year data. Overall, urethral erosion gives 
a risk of tape-related complications of 4.6% (8/175). The 
true value may be higher, however, because the full study 
population has not been surveyed beyond 5 years post-
operatively. 
　The recently published study by Meschia et al reported Korean J Urol 2010;51:223-232
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TABLE 5. Randomized controlled trials comparing complication rates among mid-urethral sling  procedures
Reference Cases
Follow-up 
(months)
Bladder/vaginal 
perforation (%)
Haematoma 
(%)
Bladder 
erosions (%)
Vaginal 
erosion (%)
Rechberger 2003 [11]
  TVT 
  IVS 
50
50
13.5 4
8
4
2
0
0
0
0
Lim 2005 [32]
  TVT 
  IVS 
61
60
1.5-3 1.6
3.3
0
0
3.3
1.7
Meschia 2006 [12]
  TVT 
  IVS 
95
95
24 3.3
3.4
1.1
3.4
0
0
0
9
Andonian 2005 [33]
  TVT 
  SPARC 
43
41
12 23
24
0
2.4
0
0
0
2.4
Lim 2005 [32]
  TVT 
  SPARC 
61
61
1.5-3 1.6
6.6
0
0
3.3
13.1
Tseng 2005 [13]
  TVT 
  SPARC 
31
31
25 0
12.9
16.1
9.7
29
9.6
Lord 2006 [34]
  TVT 
  SPARC 
147
154
20 . 7
1.9
4.1
2.6
NR
NR
NR
NR
Enzelsberger 2005 [15]
  TVT 
  Monarc 
52
53
15 7.6
0
5.7
0
1.9
1.8
Laurikainen 2007 [16]
  TVT 
  TVT-O 
136
131
2.1 2.2
2.3
0.7
0N R N R
Zullo 2007 [23]
  TVT 
  TVT-O 
35
37
16 11
0
2.8
0
0
0
0
0
MUS: mid-urethral sling, IVS: intravaginal slingplasty, NR: not reported
that vaginal erosion was significantly more common after 
IVS than after TVT (IVS, 9%; TVT, 0%; p=0.009) [12]. In 
a meta-analysis, the rate of tape erosion was lower in pa-
tients who underwent TVT, although only a nonsignificant 
trend was observed (OR: 0.26; 95% CI: 0.06-1.03; p=0.06) 
[31]. The incidence of vaginal erosion following retro pubic 
and trans-obturator tape insertion was similar. 
3. Postoperative voiding dysfunction
A multi-institutional study compared obstructive voiding 
complications between the retro pubic and trans-obturator 
procedures [37]. Obstructive complications were signi-
ficantly higher in the retro pubic group (retro pubic, 18.3%; 
trans-obturator, 11.0%). Minassian et al compared the in-
cidence of voiding dysfunction, defined as urinary retention 
or post-void residual (PVR) ＞200 ml at discharge, among 
women after three types of anti-incontinence procedures: 
63 TVT, 42 Burch colposuspension, and 33 suburethral sling 
[38]. The incidences were 50%, 15%, and 24%, respectively. 
　Previous studies have shown associated voiding dys-
function following TVT (range, 4.3-10%) [39,40], as well as 
de novo overactivity (range, 6-15%) [41,42]. Voiding dys-
function after MUS can also be related to the pre-existing 
urgency symptom, de novo urgency. According to a study 
on postoperative urgency treatment, of the 59 patients with 
pre-existing urgency, 54.2%, 35.6%, and 39.0% demon-
strated symptom persistence at postoperative 1, 6, and 12 
months, respectively [43]. Of the 32 patients without pre-
operative urgency, 3.1% and 18.8% of patients demon-
strated de novo urgency at 1 and 6 months, respectively, 
but symptom persistence to 12 months was observed in 
6.2%. Overall, urgency lasting 12 months was observed in 
25 (27.5%) of the entire cohort.
4. Other complications
Groin pain following the trans-obturator procedure is a 
troublesome complication, for both patients and surgeons. 
Laurikainen et al randomly assigned 267 patients to TVT 
or TVT-O and reported that postoperative groin pain was 
significantly more common in the TVT-O group than in the 
TVT group (16% vs. 1.5%, respectively, p＜0.001) [16]. In 
addition, patients in the TVT-O group had significantly 
longer hospital stays and needed significantly more post-
operative opiate analgesia than did the patients in the TVT Korean J Urol 2010;51:223-232
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group. They also reported a single case of retropubic hema-
toma after TVT and urinary tract infections (TVT, 8%; 
TVT-O, 13%).
MANAGEMENT OF FAILED MID-URETHRAL 
SLING FOR FEMALE STRESS URINARY 
INCONTINENCE
Although the MUS procedure is associated with high suc-
cess rates, its widespread use has led to greater number of 
failures, increasing the need for an appropriate salvage 
procedure. Current options for managing failed sling pro-
cedures include shortening of the pre-implanted tape, in-
jecting a bulking agent, repeat MUS procedures, retro pu-
bic suspension, and pubovaginal slings. 
1. Repeat mid-urethral slings after failure of the initial 
sling procedure
Liapis et al reported the outcome of TVT in 32 women with 
failed MUS, showing an objective cure rate of 77% and a 
subjective cure rate of 71% with a mean follow-up of 18.6 
months [44]. In conclusion, they stated that patients who 
showed recurrent SUI and who had adequate urethral mo-
bility might be candidates for TVT repair. A retrospective 
study with 29 women who underwent repeat MUS due to 
persistent or recurrent SUI found that the cure rate was 
75.9%, with a mean follow-up of 18.1 months after repeat 
MUS [45]. In addition, the study also showed that the app-
roach of repeat surgery can affect the outcomes when choo-
sing MUS to salvage a failed sling. The cure rate was lower 
in women who received trans-obturator slings (62.5%) than 
in women who received retro pubic slings (92.3%) after repeat 
MUS. Although the cohort of the study was too small to make 
a meaningful comparison, other studies also showed a low-
er cure rate of the trans-obturator approach as a repeat 
MUS procedure compared with the retro pubic approach 
[46,47]. A possible explanation for the difference in the cure 
rate of repeat retro pubic and trans-obturator procedures 
is the angle of the tape supporting the mid-urethra. The ret-
ro pubic sling has a U shape, which may be more supportive 
and obstructive than the trans-obturator modifications. 
Another explanation is that the approach from outside the 
trans-obturator procedure requires wider dissection of the 
periurethral area, which may cause migration of the tape. 
2. Pubovaginal sling after failed mid-urethral slings
Anti- incontinence procedures may yield a fixed, scarred 
urethra, which leads to lower success rates, as seen in pa-
tients with intrinsic sphincter deficiency (ISD) and those 
with no urethral hypermobility. Liapis et al showed a lower 
success rate (30%) among women with a fixed urethra [48]. 
Although it is difficult to compare the success rates due to 
differing primary procedures (e.g., pubovaginal sling, col-
lagen, MUS), the critical risk factor for failure that has been 
suggested in some studies is a fixed urethra [27,49-52]. 
Several studies have also looked at pubovaginal slings in 
the treatment of recurrent SUI with success rates of 50% 
to 90% [53-55]. Although the use of pubovaginal slings in 
women who have failed MUS procedures has not been stud-
ied, a pubovaginal sling may offer more advantages in 
women who have a scarred, less mobile urethra and with 
more severe degrees of ISD. 
3. Bulking agent injection after failure of the initial sling 
procedure
A peri-urethral injection in patients with a failed sling has 
shown good clinical efficacy when used to salvage failed an-
ti-incontinence procedures [56]. Of the 5 patients with fail-
ure in the study, peri-urethral injections resulted in cure 
in 3 patients and improvement in 1.
EVALUATION AND MANAGEMENT OF VOIDING 
DYSFUNCTION AFTER MID-URETHRAL SLING 
PROCEDURES
1. Evaluation of voiding dysfunction after MUS procedures
Voiding dysfunction after a sling procedure may be due to 
urethral obstruction from hyper-elevation of the bladder 
neck or an exaggerated kink in the urethra. These symp-
toms could be obstructive (hesitancy, slow stream, inter-
mittency, feeling of incomplete voiding, need to strain or 
void in the half-standing position) or irritative (pain, fre-
quency, dysuria, nocturia, urgency, urge incontinence). A 
detailed clinical history is elemental in the detection of uri-
nary symptoms suggestive of infravesical obstruction. The 
most important aspect of the history is to ascertain the ab-
sence of obstructive symptoms before the sling procedure. 
Abdominal and vaginal examinations should be performed 
to evaluate the presence of scars, erosions, residual bladder 
neck mobility, and associated prolapse. The presence of ex-
aggerated urethral or urethrovesical junction angulation 
with a high, fixed urethra located in the retro pubic area 
is suggestive of urethral hypercorrection [57]. Although 
there is no established cutoff between normal and abnor-
mal PVR, and no evidence of correlation between PVR and 
symptoms of obstructive voiding, PVR of more than 100 ml 
is considered abnormal in women [58-60]. Blaivas and 
Groutz proposed an obstruction nomogram for women on 
the basis of free maximal flow rate and maximal detrusor 
pressure during pressure-flow study [61]. The nomogram 
characterizes patients into four categories: no obstruction, 
mild obstruction, moderate obstruction, and severe ob-
struction. Massolt et al compared obstructive symptoms 
according to a standardized questionnaire with the Blaivas- 
Groutz nomogram and found no correlation between the se-
verity of symptoms and the degree of obstruction related 
to the four nomogram categories [62]. Occasionally, cystou-
rethroscopy may be indicated to rule out an eroded tape or 
tumors in the urethra or bladder [57].
　In summary, there is no specific investigation to confirm 
obstruction in patients. The diagnosis relies on several pa-
rameters that must confirm clinical suspicion. The history 
of initial symptoms following MUS procedure, low peak 
flow rate, high voiding pressure, significant PVR, and ab-Korean J Urol 2010;51:223-232
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TABLE 6. Outcome of case series involving surgical treatment of urethral obstruction after the TVT procedure
Reference
Patients, 
n
Procedure
Time to 
procedure
Recurrent 
SUI rate (%)
Follow-up
Glavind and Glavind 2007 [66] 5 Tape pull-down 2.2 weeks 0 NR
2 Midline sling incision 5 and 7 months 100 NR
Zubke et al. 2004 [67] 3 Midline sling incision and
 polypropylene mesh prolongation
NR 0 NR
Croak et al. 2003 [68] 5 Midline sling incision NR 20 NR
Rardin et al. 2002 [69] 23 Midline sling incision 17.3 weeks 13 6 weeks
Klutke et al. 2001 [70] 17 Tape release (incision or loosening) 64 days 5.9 13 months
TVT: tension-free vaginal tape, NR: not reported
normal urethral calibrating must all be considered for a 
conclusive diagnosis of urethral obstruction.
2. Management of voiding dysfunction after MUS proce-
dures
The initial management of a patient after a MUS procedure 
should place her in one of the two following categories: 
acute complete urinary retention or chronic urinary re-
tention with obstructive voiding dysfunction. If the patient 
is in the first category, a voiding trial should be performed 
within 48-72 hours following surgery. However, if the pa-
tient presents with signs and symptoms of dysfunctional 
obstructive voiding indicative of chronic urinary retention, 
the approach may vary. In an Australasian survey that in-
cluded 74 respondents who had performed 1,549 poly-
propylene sling procedures (TVT or suprapubic arc sling), 
95 cases (6.5%) of urinary retention were reported [63]. 
Most were managed conservatively by clean intermittent 
self-catheterization (38%) or indwelling urethral catheteri-
zation (35%). Thirty-three women required operative man-
agement by sling division (20%), early sling loosening by 
traction (7%), and urethrolysis with sling removal (7%). A 
combination of initial conservative management followed 
by surgery was needed in 7 patients (7%). 
　A multi-institutional review of 241 women who had un-
dergone the TVT procedure revealed 47 women who devel-
oped urinary retention for more than 24 hours. Of these 
women, 68% experienced resolution of urinary retention in 
the first 48 hours after surgery and 11% were managed 
with intermittent catheterization or an indwelling Foley 
catheter [64]. The remaining patients underwent different 
treatments: 7 had tape release and 3 had tape incision. 
There is no consensus on the appropriate surgical revision 
techniques. Tape release, urethrolysis, and sling incision 
can be options as surgical treatment for voiding dysfunc-
tion after MUS.
　The rate of recurrent SUI after surgical treatment of ure-
thral obstruction was reported to be up to 36%, except in 
a study with 2 patients [65]. Table 6 summarizes case series 
reporting the surgical management of urinary retention af-
ter sling procedures. 
　Another important issue is the optimal time for further 
treatment, such as anti-muscarinic agents in cases where 
urgency is present postoperatively. A study evaluating the 
optimal time for overactive bladder symptoms after MUS 
recommended treatment if urgency is noted at 1 month 
postoperatively in patients with pre-existing urgency and 
after 6 months for those without preoperative urgency [39]. 
CONCLUSIONS
MUS has proven efficacy and is now a mainstay in the surgi-
cal management of female SUI. Prospective data indicate 
little clinical difference between the retro pubic and the 
trans-obturator approach, or indeed between various de-
vices used within each technique. Surgeons must be pre-
pared to identify and correct postoperative complications 
and voiding dysfunction. In addition, they should be trained 
in the diagnosis and treatment of failed MUS procedures. 
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